With the potential to completely transform how we treat life-threatening diseases, cell and gene therapies are at the forefront of modern medicine. These ground-breaking biological therapies have over time become one of the most promising areas of medical therapy due to their unsurpassed ability to harness the power of our own bodies as disease-fighting agents. From fighting cancer and central nervous system disorders to addressing musculoskeletal ailments, cell and gene therapies provide a ray of hope for patients suffering from incurable diseases. Recent years have witnessed a notable increase in the field of cell and gene treatments, drawing interest from investors, healthcare professionals, and researchers alike. The enormous impact and revolutionary potential of these treatments have attracted considerable venture capital from around the globe, indicating a worldwide commitment to advance medical science innovation. With the goal of revolutionising healthcare and solving unmet medical needs, scientists and pioneers in cell and gene therapy are working relentlessly to create a future in which previously incurable diseases may be effectively controlled or may even possibly find a cure.

From 2018 to 2022, the cell and gene therapy landscape underwent a significant surge, with around 2,000 clinical trials launched globally. These trials are aimed at investigating new treatment options for people suffering from a variety of life-threatening and rare diseases. The Asia-Pacific (APAC) region stood out among the geographical regions driving this global effort, with China and the United States of North America ranking as the top locations for these ground-breaking clinical trials.

Oncology, particularly haematological tumours, has taken centre stage as the most investigated therapeutic area in the field of cell and gene therapies. The emphasis has been on cell, gene or gene modified cell therapies (particularly car-t cells) intended to battle cancer by activating the body's natural defence systems against these malignancies. Till date, more than five car-t cell treatments have been approved for the treatment of different haematological malignancies, including lymphomas and leukaemias.

A major part of these clinical trials, more than 40%, involved gene-modified cell treatments, in which patients' cells were genetically modified to target and cure specific disease conditions. The vast majority of these trials, almost 70%, were conducted in a single location, with the APAC region leading this trend. The APAC region has additionally demonstrated significant benefits in terms of trial duration and enrolment efficiency, indicating a faster pace of cutting-edge gene therapy research. However, the increase in venture capital for cell and gene therapy research and development was not restricted to the APAC area. Multiple therapeutic fields, with a particular focus on cancer therapies, saw significant increases in financing, with the United States, China, and Europe receiving the majority of these financial resources.

Automation is emerging as an important strategy in tackling the complexities of cell and gene manufacturing, which have historically been associated with high development costs. The production process may be accelerated, the costs reduced, and time to market entry expedited through the inclusion of intuitive software and Artificial Intelligence (AI)-based solutions.  These benefits, make automation a critical tool for advancing the cell and gene field and making these therapies more available to patients in need in the future.

Overall, cell and gene therapy research and development grew at an unprecedented pace between 2018 and 2022, with the APAC region leading the way in clinical trials and the United States and China driving funding efforts. As technology advances, the future of cell and gene treatments shines brightly, promising to improve healthcare and provide hope to countless patients around the world.